First Tracks Biotherapeutics Stock Rallies on Dual 'Buy' Initiations from Guggenheim, UBS

First Tracks Biotherapeutics (TRAX) stock rallied 4.5% in morning trading Wednesday following a rare double-initiation of coverage from two major Wall Street firms. The fresh endorsements significantly raised the company's institutional profile and signaled growing confidence in its clinical pipeline.

Wall Street Initiates Coverage

Guggenheim initiated coverage with a Buy rating and a $100 price target, designating the company as a new "Top Pick." In a note to clients, Guggenheim analyst Yatin Suneja highlighted the potential of First Tracks' lead drug candidate.

Adding to the bullish sentiment, UBS Group also initiated coverage on the same day with its own Buy rating. Such simultaneous initiations are uncommon and serve as a strong positive catalyst, drawing increased attention from institutional investors.

Focus on Lead Drug Candidate ANB033

The investment thesis from both firms is centered on ANB033, an anti-CD122 monoclonal antibody. The drug has shown promising early clinical results in treating several autoimmune conditions with significant unmet needs, including:

Ad

• Celiac Disease
• Eosinophilic Esophagitis
• Vitiligo

The U.S. Food and Drug Administration (FDA) has already granted ANB033 Fast Track designation for the treatment of celiac disease, potentially expediting its review process. Investors are now looking ahead to a key near-term catalyst, as the company expects to release top-line data from its Phase 1b study in the fourth quarter of 2026.

Market Context

The rally occurred amid a supportive broader market, with the Nasdaq Composite gaining 0.7% and the S&P 500 up 0.4%, reflecting a constructive appetite for growth-oriented stocks. While First Tracks' stock has more than doubled from its 52-week low of $14.72, it remains considerably below its 52-week high of $49.91, suggesting analysts see further upside potential if upcoming clinical milestones are successfully met.